| Market Cap | 1.23B 1.1B 1.01B 916M 1.73B 117B 1.77B 12.09B 4.83B 61.77B 4.63B 4.53B 195B | P/E 2026 * |
-4.47x | P/E 2027 * | -3.44x |
|---|---|---|---|---|---|
| Enterprise Value | 626M 558M 510M 465M 876M 59.15B 899M 6.13B 2.45B 31.33B 2.35B 2.3B 98.85B | EV / Sales 2026 * |
15x | EV / Sales 2027 * | 15.3x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 1.23B | |
| +3.80% | +8.10% | +63.78% | +77.70% | 69.4B | |
| -2.06% | -1.07% | +8.30% | +72.93% | 57.24B | |
| -2.54% | +1.77% | +23.33% | +97.83% | 57.62B | |
| +0.41% | -3.70% | +26.06% | +34.32% | 43.65B | |
| +2.51% | +4.22% | +20.49% | +110.71% | 44.03B | |
| -11.04% | -6.63% | +199.38% | +701.67% | 38.08B | |
| +7.50% | +13.58% | +29.07% | +64.46% | 36.31B | |
| -3.38% | -10.38% | +87.74% | +75.12% | 32.61B | |
| -2.18% | +7.06% | +36.06% | -4.95% | 25.47B | |
| Average | -0.60% | +2.80% | +54.91% | +136.64% | 44.93B | |
| Weighted average by Cap. | -0.28% | +3.12% | +51.22% | +130.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.82M 37.27M 34.09M 31.04M 58.52M 3.95B 60.09M 410M 164M 2.09B 157M 154M 6.6B | 53.42M 47.6M 43.54M 39.65M 74.74M 5.05B 76.76M 523M 209M 2.67B 201M 196M 8.44B |
| Net income | -246M -220M -201M -183M -345M -23.29B -354M -2.41B -965M -12.33B -925M -905M -38.91B | -363M -323M -296M -269M -507M -34.27B -521M -3.55B -1.42B -18.15B -1.36B -1.33B -57.27B |
| Net Debt | -608M -542M -496M -452M -851M -57.49B -874M -5.96B -2.38B -30.45B -2.28B -2.23B -96.07B | -415M -370M -338M -308M -581M -39.24B -597M -4.07B -1.63B -20.78B -1.56B -1.53B -65.58B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
